First , we searched for the most synergistic combination of KPT-8602 with dexamethasone , vincristine , or doxorubicin
The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. KPT-8602 (Eltanexor) is a second-generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in preclinical models and with minimal effects on normal cells. In this study, we evaluated whether KPT-8602 would synergize with dexamethasone, vincristine, or doxorubicin, three drugs currently used for the treatment of ALL. ### Experimental Design First , we searched for the most synergistic combination of KPT-8602 with dexamethasone , vincristine , or doxorubicin ### results KPT-8602 showed strong synergism with dexamethasone on human B-ALL and T-ALL cell lines as well as ### conclusions Our preclinical study demonstrates that KPT-8602 enhances the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1- and E2F-mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            The XPO1 Inhibitor KPT-8602 Synergizes with Dexamethasone in Acute Lymphoblastic Leukemia. KPT-8602 (Eltanexor) is a second-generation exportin-1 (XPO1) inhibitor with potent activity against acute lymphoblastic leukemia (ALL) in preclinical models and with minimal effects on normal cells. In this study, we evaluated whether KPT-8602 would synergize with dexamethasone, vincristine, or doxorubicin, three drugs currently used for the treatment of ALL. ### Experimental Design First , we searched for the most synergistic combination of KPT-8602 with dexamethasone , vincristine , or doxorubicin ### results KPT-8602 showed strong synergism with dexamethasone on human B-ALL and T-ALL cell lines as well as ### conclusions Our preclinical study demonstrates that KPT-8602 enhances the effects of dexamethasone to inhibit B-ALL and T-ALL cells via NR3C1- and E2F-mediated transcriptional complexes, allowing to achieve increased dexamethasone effects for patients.

            ### Response:
            KPT-8602, dexamethasone, vincristine, doxorubicin
            